UNITEDHEALTH GROUP INC

UnitedHealth Group announced its third quarter 2026 results, reporting revenues of $112.7 billion and earnings from operations of $6.6 billion. The company raised its full-year 2026 earnings outlook to at least $20.50 per share. Key financial metrics showed improved earnings from operations and a lower medical cost ratio compared to the prior year. Additionally, UnitedHealth Group committed $1 billion to the United Health Foundation to support initiatives in rural health, maternal and children's health, and behavioral health.

UnitedHealth Group reported strong second quarter 2026 results, with revenues reaching $112.0 billion and adjusted earnings of $6.38 per share. The company also raised its full-year 2026 adjusted earnings outlook to a range of $19.50 to $20.00 per share, reflecting improved performance and outlook. Key initiatives include reforms in prior approvals, pharmacy benefits, and investments in technology and community support, alongside increased share repurchases and cash flow from operations.

UnitedHealth Group Incorporated announced that its senior leaders will participate in the Bank of America Securities Health Care Conference 2026. The presentation, scheduled for May 12, 2026, at 11:00 a.m. Eastern Time, will feature an interview format where leaders will discuss the company's strategy, market positions, recent results, and expectations for its end markets. A live audio webcast of the event will be available on the company's investor relations website.

UnitedHealth Group reported Q1 2026 total revenues of $111.72 billion, an increase from the prior year, with diluted earnings per share rising to $6.90. Operating cash flows saw a substantial increase to $8.91 billion. The company also recognized a net gain of $230 million from portfolio divestitures and entered into forward contracts for up to $2.0 billion in common stock repurchases, while facing ongoing legal and tax challenges.

UnitedHealth Group reported strong first-quarter 2026 results, with revenues growing 2% year-over-year to $111.7 billion and adjusted earnings per share of $7.23. The company's medical cost ratio improved by 90 basis points to 83.9%, reflecting operational efficiencies. Strategic actions include exiting non-U.S. businesses, leadership changes, and investments in AI and cybersecurity. The company also announced the acquisition of Alegeus Technologies and a $2 billion share buyback program, while reaffirming its full-year adjusted net earnings outlook of over $18.25 per share.

UnitedHealth Group (UNH) released its third quarter 2025 results, as announced in a press release on October 28, 2025. The full details of the financial performance are available in the furnished exhibit, which investors will analyze to assess the company's profitability, growth, and overall financial health.

UnitedHealth Group will participate in the UBS Global Healthcare Conference 2025 on November 10, 2025. Senior leaders will discuss the company's strategy, market positions, recent results, and expectations for its end markets. A live audio webcast will be available on the company's investor relations website.

UnitedHealth Group appointed Scott Gottlieb, M.D., former FDA commissioner, as an independent director, effective immediately. Gottlieb's experience in healthcare regulation and policy, including his tenure at the FDA, CMS, and other health organizations, is expected to provide valuable insights to UnitedHealth Group.

UnitedHealth Group's senior management will meet with investors on January 12, 2026, and intends to reaffirm its previously disclosed adjusted 2025 earnings per share (EPS) expectations. The company cautions that actual results may change due to financial closing procedures and other developments.

UnitedHealth Group reported full-year 2025 results, with revenues of $447.6 billion, a 12% year-over-year increase, and earnings of $13.23 per share. The company issued a 2026 revenue outlook greater than $439.0 billion and adjusted earnings greater than $17.75 per share, indicating continued growth expectations. The company also took a $1.6 billion charge related to cyberattack costs, portfolio divestitures, and restructuring.